Abstract: The present disclosure provides gene therapy expression constructs comprising a nucleic acid encoding a therapeutic anti-TNFalpha antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof, delivery vectors (e.g., viral vectors) comprising the same, compositions comprising the same, and methods of using the same (e.g., to treat ocular diseases or disorders). Some aspects of the disclosure are directed to a recombinant adeno-viral vector (rAAV) delivery comprising an AAV particle (e.g., AAV2) and a nucleic acid encoding a therapeutic anti-TNFalpha antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof.

Abstract: According to one exemplary embodiment, an integrated circuit chip comprises an oxide region. The integrated circuit chip further comprises a poly resistor having a first terminal and second terminal, where the poly resistor is situated over the oxide region. According to this exemplary embodiment, the integrated circuit chip further comprises a metal resistor having a first terminal and a second terminal, where the metal resistor is situated over the poly resistor, and where the first terminal of the metal resistor is connected to the first terminal of the poly resistor. According to this exemplary embodiment, the integrated circuit chip may further comprise a first metal segment connected to the second terminal of the metal resistor and a second metal segment connected to the second terminal of the poly resistor. The integrated circuit chip may further comprise an inter-layer dielectric situated between the poly resistor and the metal resistor.